ALK and neoplasm: Personalized care using molecular profiling of tumor tissues from serial biopsies at progression on multiple lines of ALKi therapy was exemplified in a landmark case report revealing paradoxical resensitization to crizotinib at the emergence of a compound ALK L1198F/C1156Y mutation, with then durable re-response (107).